KRAS and pancreatic neoplasm: There are currently several recruiting clinical trials for VS-6766 in combination with: adagrasib (in KRAS G12C NSCLC patients; NCT05375994), sotorasib (in KRAS G12C NSCLC patients; NCT05074810) or defactinib with gemcitabine and nab-paclitaxel (in patients with pancreatic cancer; NCT05669482).